Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.

Carriere CH, Kang NH, Niles LP.

Neuroscience. 2014 May 16;267:114-21. doi: 10.1016/j.neuroscience.2014.02.028. Epub 2014 Mar 6.

PMID:
24613722
2.

Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.

Carriere CH, Kang NH, Niles LP.

Brain Res. 2016 Feb 15;1633:115-25. doi: 10.1016/j.brainres.2015.12.036. Epub 2015 Dec 29.

PMID:
26740407
3.

Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.

Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A.

Neurotox Res. 2010 Feb;17(2):130-41. doi: 10.1007/s12640-009-9090-5. Epub 2009 Jul 21.

PMID:
19626387
4.

Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.

Carriere CH, Kang NH, Niles LP.

Exp Toxicol Pathol. 2017 Feb;69(2):109-114. doi: 10.1016/j.etp.2016.12.007. Epub 2016 Dec 13.

PMID:
27986376
5.

Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.

Salama M, Ellaithy A, Helmy B, El-Gamal M, Tantawy D, Mohamed M, Sheashaa H, Sobh M, Arias-Carrión O.

CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):836-43.

PMID:
23198691
6.

Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.

Yin LH, Shen H, Diaz-Ruiz O, Bäckman CM, Bae E, Yu SJ, Wang Y.

BMC Neurosci. 2012 Oct 6;13:120. doi: 10.1186/1471-2202-13-120.

7.

Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.

Salama M, Helmy B, El-Gamal M, Reda A, Ellaithy A, Tantawy D, Mohamed M, El-Gamal A, Sheashaa H, Sobh M.

Environ Toxicol Pharmacol. 2013 Mar;35(2):270-7. doi: 10.1016/j.etap.2012.12.008. Epub 2013 Jan 7.

PMID:
23357603
8.

L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.

Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP.

Neurochem Int. 2006 Jul;49(1):28-40. Epub 2006 Feb 21.

PMID:
16490285
10.

Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.

Khurana N, Gajbhiye A.

Neurotoxicology. 2013 Dec;39:57-64. doi: 10.1016/j.neuro.2013.08.005. Epub 2013 Aug 28.

PMID:
23994302
11.
12.
13.

The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.

Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E.

Behav Brain Res. 2013 Apr 15;243:6-15. doi: 10.1016/j.bbr.2012.12.051. Epub 2013 Jan 4.

PMID:
23295396
15.

Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.

Norazit A, Meedeniya AC, Nguyen MN, Mackay-Sim A.

Brain Res. 2010 Nov 11;1360:119-29. doi: 10.1016/j.brainres.2010.08.070. Epub 2010 Aug 31.

PMID:
20807515
16.

Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.

Sharma R, McMillan CR, Tenn CC, Niles LP.

Brain Res. 2006 Jan 12;1068(1):230-6. Epub 2005 Dec 20.

PMID:
16375867
17.

The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.

Thomas Tayra J, Kameda M, Yasuhara T, Agari T, Kadota T, Wang F, Kikuchi Y, Liang H, Shinko A, Wakamori T, Vcelar B, Weik R, Date I.

Brain Res. 2013 Mar 28;1502:55-70. doi: 10.1016/j.brainres.2013.01.042. Epub 2013 Feb 1.

18.

The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.

Datla KP, Bennett RD, Zbarsky V, Ke B, Liang YF, Higa T, Bahorun T, Aruoma OI, Dexter DT.

J Pharm Pharmacol. 2004 May;56(5):649-54.

PMID:
15142343
19.

Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.

Carbone M, Duty S, Rattray M.

BMC Neurosci. 2012 Apr 5;13:38. doi: 10.1186/1471-2202-13-38.

20.

Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.

Aponso PM, Faull RL, Connor B.

Neuroscience. 2008 Feb 19;151(4):1142-53. doi: 10.1016/j.neuroscience.2007.11.036. Epub 2007 Dec 4.

PMID:
18201835

Supplemental Content

Support Center